Phase II UC-MSCs Knee Osteoarthritis Trial, Apr 2026
Summary
NIH registered Phase II clinical trial NCT07547735 evaluating umbilical cord mesenchymal stem cell (UC-MSC) injection versus placebo for treatment of knee osteoarthritis. The trial is listed on ClinicalTrials.gov with an estimated completion date of April 23, 2026. The abstract cites the growing global burden of knee osteoarthritis (ranked 11th in global disability diseases) and notes that most current treatments provide only pain relief without preventing cartilage damage, positioning UC-MSC transplantation as a novel therapeutic approach with potential regenerative benefits for mild to moderate cartilage defects.
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NIH added a new Phase II clinical trial registration (NCT07547735) to ClinicalTrials.gov for a study evaluating human umbilical cord mesenchymal stem cell (UC-MSC) injection as a treatment for knee osteoarthritis. The trial uses a randomized, placebo-controlled design and lists UC-MSCs as the active intervention with no specific firm or sponsor named in the registration abstract.
Healthcare providers and clinical investigators involved in orthopaedic or regenerative medicine research should note this trial's registration as a signal of ongoing investigation into stem cell-based therapies for cartilage repair. Sponsors of applicable clinical trials under FDAAA 801 should ensure compliance with ClinicalTrials.gov registration and results posting requirements.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Phase II Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis
Phase 2 NCT07547735 Kind: PHASE2 Apr 23, 2026
Abstract
In recent years, the incidence rate and disability rate of osteoarthritis have continued to grow, and it has become a common chronic disease of elderly patients, second only to the "three highs", and poses a continuous threat to China's medical and health system and public health system. Knee osteoarthritis is the main type of osteoarthritis, ranking 11th in global disability diseases and 38th in disability adjusted life year loss, causing significant economic burden to patients, families, and society. At present, most of the treatment methods for KOA have limited efficacy, only relieving pain symptoms and cannot prevent cartilage damage and other tissue damage in the joints. Due to the limitations of adverse events, there is still no optimal treatment plan for KOA. Most studies believe that autologous mesenchymal stem cell transplantation is a new treatment method with good efficacy and good repair effect for mild to moderate cartilage defects. Given that there is currently no optimal treatment plan for KOA, human umbilical cord mesenchymal stem cell injection has potential development value and is of great significance for the treatment of KOA patients.
Conditions: Knee Osteoarthritis
Interventions: UC-MSCs, UC-MSCs, placebo
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.